Journal of the advanced practitioner in oncology最新文献

{"title":"Introduction","authors":"Beth Faiman, PhD, MSN, APRN-BC, AOCN®, BMTCN, FAAN, Tiffany Richards, PhD, ANP-BC, AOCNP","doi":"10.6004/jadpro.2022.13.5.9","DOIUrl":"https://doi.org/10.6004/jadpro.2022.13.5.9","url":null,"abstract":"Advances in the diagnosis and management of multiple myeloma (MM) and other plasma cell disorders such as AL amyloidosis and Waldenström macroglobulinemia (WM) continue to evolve rapidly. Over the past several years, there have been significant gains in understanding disease biology, leading to improvements in diagnostic techniques, a shift towards targeted therapies, and a potential transition away from traditional chemotherapeutic agents as the standard of care.","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44179703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pull Up a Seat: Engaging Patients as Empowered Partners in Health Equity Transformation","authors":"Maimah Karmo, A. Pierre","doi":"10.6004/jadpro.2022.13.3.3","DOIUrl":"https://doi.org/10.6004/jadpro.2022.13.3.3","url":null,"abstract":"At the JADPRO Live Virtual 2021 keynote interview, Maimah Karmo, CEO and Founder of the Tigerlily Foundation, spoke with Amy Pierre, MSN, ANP-BC, on her breast cancer experience and drive to establish an organization that educates, advocates for, and empowers young women of color at every stage of their breast cancer journey. Ms. Karmo and Ms. Pierre also discussed the role of the advanced practitioner in furthering patient-centered, equitable care.","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":"13 1","pages":"202 - 204"},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44651275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mental Health in the Oncology Setting: General Considerations and Treatment Tips.","authors":"Lisa W Goldstone","doi":"10.6004/jadpro.2022.13.3.12","DOIUrl":"https://doi.org/10.6004/jadpro.2022.13.3.12","url":null,"abstract":"<p><p>Patients with comorbid mental health and substance use disorders are at greater risk for mortality and have higher cancer care costs. At JADPRO Live Virtual 2021, Lisa W. Goldstone, MS, PharmD, BCPS, BCPP, talked through general considerations in the oncology setting for persons with comorbid mental health or substance use disorders, strategies for recognizing when patients with new or preexisting mental health symptoms or disorders may benefit from treatment and/or referral, and first and second-line pharmacotherapy options.</p>","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":"13 3","pages":"243-246"},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126327/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71490604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardio-Oncology Considerations in Oncologic Treatment Decisions.","authors":"Anecita P Fadol","doi":"10.6004/jadpro.2022.13.3.11","DOIUrl":"https://doi.org/10.6004/jadpro.2022.13.3.11","url":null,"abstract":"<p><p>At JADPRO Live Virtual 2021, presenter Anecita P. Fadol, PhD, FNP-BC, FAANP, FAAN, emphasized the critical role advanced practitioners play in the identification, monitoring, and management of the cardiac complications of cancer therapy. Dr. Fadol's presentation discussed identification of the most common cardiotoxicities associated with cancer therapy, clinical considerations related to common oncologic treatments with potential cardiotoxicity that may impact cancer treatment decisions, and the management of common cardiovascular issues in patients with cancer.</p>","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":"13 3","pages":"237-242"},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126328/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142928944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular Testing in Hematologic Malignancies","authors":"L. Zitella","doi":"10.6004/jadpro.2022.13.3.29","DOIUrl":"https://doi.org/10.6004/jadpro.2022.13.3.29","url":null,"abstract":"Molecular testing technologies have been increasingly integrated into clinical research and are essential tools in the care of patients with hematologic malignancies. During this session at JADPRO Live Virtual 2021, Laura J. Zitella, MS, RN, ACNP-BC, AOCN®, reviewed key concepts for diagnostic testing with a focus on molecular testing (including cytogenetics, FISH, PCR, and next-generation sequencing) and discussed how to interpret the results for hematologic malignancies to inform prognosis as well as treatment.","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":"13 1","pages":"324 - 327"},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45830307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ASH Highlights and Commentary: Myeloid Malignancies","authors":"Lindsey Lyle, MS, PA-C","doi":"10.6004/jadpro.2022.13.2.11","DOIUrl":"https://doi.org/10.6004/jadpro.2022.13.2.11","url":null,"abstract":"This supplement to JADPRO provides an overview of several abstracts that were presented at the 2021 ASH Annual Meeting, along with expert commentary that aims to contextualize the information presented at ASH for the advanced practitioner. Lindsey Lyle, MS, PA-C, of University of Colorado Anschutz Medical Campus, considers promising results in the myeloid malignancies space. Ms. Lyle highlights long-term data on the combination of eprenetapopt (APR-246) and azacitidine in patients with TP53-mutated acute myeloid leukemia/myelodysplastic syndromes, a new option for patients with paroxysmal nocturnal hemoglobinuria, and valuable insights into Black and non-Black patient preferences regarding their treatment and communication with their providers.","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":"13 1","pages":"15 - 23"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48135296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incorporating Scientific Advances and Improving Access to Care: Meeting Abstracts From the 2021 ASH Annual Meeting and Exposition","authors":"S. Kurtin","doi":"10.6004/jadpro.2022.13.2.9","DOIUrl":"https://doi.org/10.6004/jadpro.2022.13.2.9","url":null,"abstract":"","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":"13 1","pages":"3 - 4"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41770068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Music on Postoperative Pain, Anxiety, and Narcotic Use After Robotic Prostatectomy: A Randomized Controlled Trial.","authors":"Kirtishri Mishra, Erin Jesse, Laura Bukavina, Emily Sopko, Itunu Arojo, Austin Fernstrum, Al Ray, Amr Mahran, Adam Calaway, Seneca Block, Lee Ponsky","doi":"10.6004/jadpro.2022.13.2.3","DOIUrl":"https://doi.org/10.6004/jadpro.2022.13.2.3","url":null,"abstract":"<p><strong>Background: </strong>Music is a safe and cost-effective intervention that can reduce postoperative pain and anxiety. We investigated the effects of music therapy on postoperative recovery in patients undergoing robotic-assisted laparoscopic prostatectomy (RALP).</p><p><strong>Methods: </strong>Subjects were males 18 years and older undergoing RALP at a single tertiary care institution. Patients were randomized to music or control groups. The music group received 30 minutes of music in the recovery area and on postoperative day (POD) 1, while the control group was not provided postoperative music. Inpatient narcotic use (morphine milligram equivalent, or MME) and outpatient narcotic use were measured, and the State-Trait Anxiety Inventory (STAI) survey was completed on POD 1 and POD 7 by an inpatient advanced practitioner (AP). T-test and Chi-square were used to compare the groups. Linear regression was used to adjust for age, blood loss, and inpatient MME.</p><p><strong>Results: </strong>A total of 40 patients were prospectively recruited. There was no statistically significant difference in the hourly MME (2.06 [0.71-3.17] vs. 1.55 [0.83-3.37]) or total MME (49.52 [17-76] vs. 37.25 [20-69]) used in the music vs. non-music arms, respectively. Evaluation of STAI questionnaire revealed no overall differences in anxiety levels among the two groups on POD 1 or POD 7. After adjusting for age, blood loss, and inpatient MME use, patients assigned to the music intervention had a 26% reduction in post-hospitalization use.</p><p><strong>Conclusion: </strong>Our prospective randomized study suggests that music can be an AP-driven adjunct to facilitate postoperative patient comfort and reduce narcotic use upon discharge in prostate cancer patients.</p>","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":"13 2","pages":"121-126"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955566/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142047667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ASH Highlights and Commentary: Additional Topics of Interest","authors":"J. Zurko, N. Epperla, -. Im, ran Nizamuddin, P. Torka, K. David, T. Ollila, B. Hess, Jonathon B. Cohen, R. Ferdman, Jieqi Liu, Sayan Mullick, Chowdhury, Kaitlyn L. O'Shea, Jason T. Romancik, R. Bhansali, E. Harris, M. Sorrell, R. Masel, L. Fitzgerald, C. Galvez, J. Winter, B. Pro, Léo, I. Gordon, A. Danilov, N. Shah, G. Shouse, Vaishalee, P. Kenkre, S. Barta","doi":"10.6004/jadpro.2022.13.2.12","DOIUrl":"https://doi.org/10.6004/jadpro.2022.13.2.12","url":null,"abstract":"884 Outcomes and Treatment Patterns in Patients With Aggressive B-Cell Lymphoma After Failure of Anti-CD19 CAR T-Cell Therapy Joanna C. Zurko, MD, Narendranath Epperla, MD, MS, Imran Nizamuddin, MD, Pallawi Torka, MD, Kevin A. David, MD, Thomas A. Ollila, MD, Brian T. Hess, MD, Jonathon B. Cohen, MD, MS, Robert Ferdman, MD, Jieqi Liu, MD, Sayan Mullick Chowdhury, DO, PhD, Kaitlyn O’Shea, PhD, Jason Romancik, MD, Rahul Bhansali, MD, Elyse Harris, MD, Mckenzie Sorrell, D.O., Rebecca Masel, Lindsey Fitzgerald, MD, Carlos Galvez, MD, Shuo Ma, MD, Jane N. Winter, MD, Barbara Pro, MD, Leo I. Gordon, MD, Alexey V. Danilov, MD, PhD, Deborah M. Stephens, Nirav N. Shah, MD, Geoffrey Shouse, PhD, Vaishalee P. Kenkre, MD, Stefan K. Barta, MD, MRCP, MS and Reem Karmali, MD, MSc Visit https://doi.org/10.1182/blood-2021-147433 for a complete list of contributor affiliations and full graphics. Background: Anti-CD19 chimeric antigen receptor T-cell therapy (CART) is a highly active therapy for relapsed/refractory (R/R) aggressive B-cell lymphoma. Nonetheless, most patients (pts) ultimately develop progressive disease (PD). There is little guidance on the optimal treatment approach(es) for these pts. We performed a multicenter retrospective analysis with a primary objective to assess treatment patterns and outcomes in pts with R/R aggressive B-cell lymphoma who develop PD after anti-CD19 CARTs. Methods: Pts with aggressive B-cell lymphoma treated with anti-CD19 CART between 2015 and 2020 across 12 US academic medical centers were included. Demographic and clinical characteristics were collected along with CART toxicities and response. Regimens administered as salvage post CART were assessed. Univariate analyses (UVA) were performed to determine impact of demographic and clinical variables on survival outcomes. All p-values were two-tailed. Survival curves were calculated using the KaplanMeier method. Results: A total of 400 pts received anti-CD19 CARTs and were included for analysis. For the entire cohort: median PFS and OS from time of CART infusion were 11 months [mo] and 27 mo respectively. On log-rank testing, pts who received ≥3 lines of pre-CART therapy and those with refractory disease pre-CART had significantly worse PFS (p=0.004 & 0.001) and OS (both p<0.001). With median follow-up 22.4 mo, 190 pts (48%) had PD after CART; demographic and clinical variables of pts with and without PD are detailed in Table 1. Biopsy to confirm PD and assess CD19 status was done in 69 pts (36%) with CD19 negative relapse seen in 11 (16%). Of pts with PD, median PFS and OS from time of PD was 83 days (in pts who received salvage) and 174 days (for all PD pts) respectively. Pts with PD were more likely to have elevated LDH (p=0.001) and extranodal disease (p=0.003) at apheresis. For pts with PD after CART: 125 (65.5%) received further therapies. Pts were more likely to receive salvage therapies if their best response to CART was CR (p=0.026) or PR (p=0.015). Response rates of","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":"13 1","pages":"25 - 32"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46203285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Myasthenia Gravis: A Rare Neurologic Complication of Immune Checkpoint Inhibitor Therapy.","authors":"Yelena Shames, Mimma Errante, Nana Prempeh Keteku","doi":"10.6004/jadpro.2022.13.2.6","DOIUrl":"https://doi.org/10.6004/jadpro.2022.13.2.6","url":null,"abstract":"<p><p>Myasthenia gravis is an autoimmune disorder affecting the neuromuscular junction, which is characterized by the production of autoimmune antibodies to acetylcholine or muscle-specific kinase receptors, causing an error in transmission of nerve impulses to various muscles. The hallmark of myasthenia gravis is \"grave or serious\" fluctuating muscle weakness. Ocular, respiratory, bulbar, and skeletal muscles are most commonly affected; therefore, patients often present with fatigable ptosis, blurry vision, diplopia, change in facial expression, dysphagia, dysarthria, dyspnea, and limb weakness. Many medications, including fluroquinolone, aminoglycoside, magnesium sulfate, quinidine, and select beta blockers, are known to unmask or exacerbate symptoms of myasthenia gravis. Although the pathogenesis is not entirely understood, T lymphocytes are thought to play a role by blocking the acetylcholine receptors and causing antibody production. In the era of new immune-modulating therapies emerging for treatment of different cancers, their role in inducing a proinflammatory state has become apparent, thus highlighting a clear need to increase awareness about their role in inducing myasthenia gravis or myasthenia-like symptoms.</p>","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":"13 2","pages":"151-157"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955569/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142047668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}